

Articles in 2018 with ADx involvement

1. [C-Reactive Protein, Plasma Amyloid- \$\beta\$ Levels, and Their Interaction With Magnetic Resonance Imaging Markers.](#)
 Hilal S, Ikram MA, Verbeek MM, Franco OH, **Stoops E, Vanderstichele H**, Niessen WJ, Vernooij MW.
Stroke. 2018 Nov;49(11):2692-2698. doi: 10.1161/STROKEAHA.118.022317

2. [Cerebrospinal Fluid Total and Phosphorylated \$\alpha\$ -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.](#)
 Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, **Vanderstichele H, Demeyer L, Stoops E**, Trojanowski JQ, Lee VM, Zerr I.
Mol Neurobiol. 2018 Aug 22. doi: 10.1007/s12035-018-1313-4. [Epub ahead of print]

3. [Antibody-based methods for the measurement of \$\alpha\$ -synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.](#)
 Mollenhauer B, DuBois BF, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty IM, Smith CL, **Stoops E, Vanderstichele H**, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.
J Neurochem. 2018 Aug 20. doi: 10.1111/jnc.14569. [Epub ahead of print]

4. [Plasma amyloid- \$\beta\$ levels, cerebral atrophy and risk of dementia: a population-based study.](#)
 Hilal S, Wolters FJ, Verbeek MM, **Vanderstichele H**, Ikram MK, **Stoops E**, Ikram MA, Vernooij MW.
Alzheimers Res Ther. 2018 Jun 30;10(1):63. doi: 10.1186/s13195-018-0395-6

5. [Commutability of the certified reference materials for the standardization of \$\beta\$ -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and \$\beta\$ -amyloid 1-40 measurements.](#)
 Andreasson U, Kuhlmann J, Pannee J, Umek RM, **Stoops E, Vanderstichele H**, Matzen A, Vandijck M, Dauwe M, Leinenbach A, Rutz S, Portelius E, Zegers I, Zetterberg H, Blennow K.
Clin Chem Lab Med. 2018 Nov 27;56(12):2058-2066. doi: 10.1515/cclm-2018-0147

6. [The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.](#)
 Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, **Vanderstichele H**, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K.
Alzheimers Dement. 2018 Oct;14(10):1313-1333. doi: 10.1016/j.jalz.2018.05.008. Epub 2018 Jun 23. Review.

7. [Relevance of A \$\beta\$ 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM_R Scale.](#)
 Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, Maceski A, Navucet S, Paquet C, Dumurgier J, **Vanmechelen E, Vanderstichele H**, Gabelle A.
Front Aging Neurosci. 2018 May 28;10:138. doi: 10.3389/fnagi.2018.00138. eCollection 2018.

8. [Plasma A \$\beta\$ \(Amyloid- \$\beta\$ \) Levels and Severity and Progression of Small Vessel Disease.](#)
 van Leijssen EMC, Kuiperij HB, Kersten I, Bergkamp MI, van Uden IWM, **Vanderstichele H, Stoops E**, Claassen JAHR, van Dijk EJ, de Leeuw FE, Verbeek MM.
Stroke. 2018 Apr;49(4):884-890. doi: 10.1161/STROKEAHA.117.019810. Epub 2018 Mar 14

9. [Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays.](#)
Gille B, Dedeene L, **Stoops E**, **Demeyer L**, Francois C, Lefever S, De Schaepdryver M, Brix B, Vandenberghe R, Tournoy J, **Vanderstichele H**, Poesen K.
SLAS Technol. 2018 Apr;23(2):188-197. doi: 10.1177/2472630317750378. Epub 2018 Jan 18.
10. [Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.](#)
Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D, Silbert B, **Vanderstichele H**, Masters CL, Darby DG, Li QX, Collins S; AIBL Research Group.
J Alzheimers Dis. 2018;61(1):169-183. doi: 10.3233/JAD-170128
11. [Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study.](#)
Schipke CG, **De Vos A**, Fuentes M, **Jacobs D**, **Vanmechelen E**, Peters O.
Dement Geriatr Cogn Dis Extra. 2018 Aug 6;8(2):277-289. doi: 10.1159/000489847. eCollection 2018 May-Aug
12. [Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples.](#)
Pérez-Ruiz E, Decrop D, Ven K, Tripodi L, Leirs K, Rosseels J, van de Wouwer M, Geukens N, **De Vos A**, **Vanmechelen E**, Winderickx J, Lammertyn J, Spasic D.
Anal Chim Acta. 2018 Jul 26;1015:74-81. doi: 10.1016/j.aca.2018.02.011. Epub 2018 Feb 17.
13. [Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study.](#)
Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, **Vanmechelen E**, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE.
Clin Chem. 2018 Jun;64(6):927-937. doi: 10.1373/clinchem.2017.283028. Epub 2018 Mar 9.
14. [Cerebrospinal fluid neurogranin/ \$\beta\$ -site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease.](#)
Kirsebom BE, Nordengen K, Selnes P, Waterloo K, Torsetnes SB, Gísladóttir B, Brix B, **Vanmechelen E**, Bråthen G, Hessen E, Aarsland D, Fladby T
Alzheimers Dement (N Y). 2018 Nov 10;4:617-627. doi: 10.1016/j.trci.2018.10.003. eCollection 2018.

